1. Satoyoshi T, Hirohashi Y, Okuya K, Miyo M, Akizuki E, Ishii M, Miura R, Kubo T, Murata K, Kanaseki T, Tsukahara T, Takemasa I, Torigoe T. CD8-positive T Cell Infiltration With Human Leukocyte Antigen Class 1 Expression Predicts Patients With Stage IV Colorectal Cancer Survival. Anticancer Res. 2024. 44:1603-10. doi: 10.21873/anticanres.16958
2. Minowa T, Murata K, Mizue Y, Murai A, Nakatsugawa M, Sasaki K, Tokita S, Kubo T, Kanaseki T, Tsukahara T, Handa T, Sato S, Horimoto K, Kato J, Hida T, Hirohashi Y, Uhara H, Torigoe T. Single-cell profiling of acral melanoma infiltrating lymphocytes reveals a suppressive tumor microenvironment. Sci Transl Med. 2024. 16:eadk8832. doi: 10.1126/scitranslmed.adk8832
3. Fusagawa M, Tokita S, Murata K, Mariya T, Umemoto M, Sugita S, Matsuo K, Hirohashi Y, Saito T, Kanaseki T, Torigoe T. Identification and phenotypic characterization of neoantigen-specific cytotoxic CD4+ T cells in endometrial cancer. Cancer Immunol Res. 2024. doi: 10.1158/2326-6066.Cir-24-0514
4. Matsumoto S, Tsujikawa T, Tokita S, Mohamed Bedeir M, Matsuo K, Hata F, Hirohashi Y, Kanaseki T, Torigoe T. HLA class II neoantigen presentation for CD4(+) T cell surveillance in HLA class II-negative colorectal cancer. Oncoimmunology. 2024. 13:2404665. doi: 10.1080/2162402x.2024.2404665
5. Shogase N, Minowa T, Kato J, Horimoto K, Sato S, Hida T, Hirohashi Y, Torigoe T, Uhara H. Characterization of CD4 T-cell phenotype in human leukocyte antigen class II-positive acral melanoma. J Dermatol. 2024. 51:e170-e2. doi: 10.1111/1346-8138.17070
6. Shirosaki T, Kawai N, Ebihara Y, Murai A, Kubo T, Morita R, Murata K, Kanaseki T, Tsukahara T, Shichinohe T, Hirohashi Y, Hirano S, Torigoe T. Aldehyde Dehydrogenese-1 High Cancer Stem-like Cells/Cancer-initiating Cells Escape from Cytotoxic T Lymphocytes due to Lower Expression of Human Leukocyte Antigen Class 1. Anticancer Res. 2024. 44:1877-83. doi: 10.21873/anticanres.16989
7. Kubo T, Asano S, Sasaki K, Murata K, Kanaseki T, Tsukahara T, Hirohashi Y, Torigoe T. Assessment of cancer cell-expressed HLA class I molecules and their immunopathological implications. Hla. 2024. 103:e15472. doi: 10.1111/tan.15472
8. Tokita S, Kanaseki T, Torigoe T. Neoantigen prioritization based on antigen processing and presentation. Front Immunol. 2024. 15:1487378. doi: 10.3389/fimmu.2024.1487378
9. Tokita S, Fusagawa M, Matsumoto S, Mariya T, Umemoto M, Hirohashi Y, Hata F, Saito T, Kanaseki T, Torigoe T. Identification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes. Sci Adv. 2024. 10:eado6491. doi: 10.1126/sciadv.ado6491
10. Hane Y, Tsuchikawa T, Nakamura T, Hatanaka KC, Sasaki K, Kawai N, Takeuchi S, Tanaka K, Nakanishi Y, Asano T, Noji T, Shichinohe T, Hatanaka Y, Hirohshi Y, Torigoe T, Hirano S. Survivin as a Therapeutic Target for Neuroendocrine Neoplasms. Neuroendocrinology. 2025. 115:295-307. doi: 10.1159/000543270